Prudentia Sciences
Mission
Prudentia Sciences' AI-powered technology accelerates investment in breakthrough therapies that change the world.
- Empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact.
- Enabling investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking.
- Equipping investors with data-driven insights to optimize capital allocation in drug asset transactions.
Offerings and Solutions
Prudentia Sciences provides real-time data-driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
They offer rapid AI-powered synthesis of dataroom into an asset assessment framework that enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers.
AI-guided product profiles and asset valuations guide portfolio strategy and decision making.
A concise and prioritized review of risks and opportunities for drug asset staging for emerging biotech and pharma.
Traceable AI with evidence-based insights, transparent and explainable AI, Expert in the Loop with human expertise integrated with AI insights, security features including customer-level data isolation, advanced data encryption, and granular access control, and an enterprise scalable platform supporting large teams and workflows with fast, reliable performance at scale.
Company Impact and Highlights
Scientific due diligence in the life sciences industry is manual, multidisciplinary, complex, resource intensive and has persistent disconnect between scientific potential, clinical reality and financial valuation. Prudentia Sciences addresses these challenges with their platform.
The platform enables organizations to expand capacity and resources to review more deals, improve collaboration with domain experts, understand and maximize value drivers for assets, allocate capital efficiently, produce term sheets faster, and access industry experts and analytics to evaluate investments.
It is designed to unlock the full potential of drug development and commercialization, optimizing every dollar spent for impact.
Target Users
Prudentia Sciences supports various users including pharma (CEO & CFO, R&D, Business Development & Licensing), biotech (Scientific Founders, Business Development Lead), and investors (VC & PE, Hedge Funds).
Website and LinkedIn
Website: https://www.prudentiasciences.com
